- Home
- UCL vs TCRX Comparison
UCL vs TCRX Comparison
Compare UCL & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UCL
- TCRX
- Stock Information
- Founded
- UCL 2014
- TCRX 2018
- Country
- UCL Hong Kong
- TCRX United States
- Employees
- UCL N/A
- TCRX N/A
- Industry
- UCL Telecommunications Equipment
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- UCL Consumer Discretionary
- TCRX Health Care
- Exchange
- UCL Nasdaq
- TCRX Nasdaq
- Market Cap
- UCL 144.5M
- TCRX 140.7M
- IPO Year
- UCL 2020
- TCRX 2021
- Fundamental
- Price
- UCL $2.22
- TCRX $1.08
- Analyst Decision
- UCL
- TCRX Strong Buy
- Analyst Count
- UCL 0
- TCRX 6
- Target Price
- UCL N/A
- TCRX $8.80
- AVG Volume (30 Days)
- UCL 18.0K
- TCRX 880.8K
- Earning Date
- UCL 11-12-2025
- TCRX 11-07-2025
- Dividend Yield
- UCL N/A
- TCRX N/A
- EPS Growth
- UCL N/A
- TCRX N/A
- EPS
- UCL 0.02
- TCRX N/A
- Revenue
- UCL $89,277,000.00
- TCRX $6,961,000.00
- Revenue This Year
- UCL N/A
- TCRX $255.18
- Revenue Next Year
- UCL $20.86
- TCRX N/A
- P/E Ratio
- UCL $96.16
- TCRX N/A
- Revenue Growth
- UCL 3.72
- TCRX N/A
- 52 Week Low
- UCL $0.80
- TCRX $1.02
- 52 Week High
- UCL $4.19
- TCRX $6.23
- Technical
- Relative Strength Index (RSI)
- UCL 47.65
- TCRX 25.12
- Support Level
- UCL $2.10
- TCRX $1.08
- Resistance Level
- UCL $2.25
- TCRX $1.17
- Average True Range (ATR)
- UCL 0.12
- TCRX 0.17
- MACD
- UCL 0.02
- TCRX -0.14
- Stochastic Oscillator
- UCL 41.38
- TCRX 0.68
About UCL uCloudlink Group Inc.
Ucloudlink Group Inc is engaged in the provision of data connectivity services and sales of Wi-Fi terminals and data related products to enable personal and enterprise users to access mobile internet in more than 100 countries and areas. Leveraging its inventive cloud SIM technology and architecture, the company redefine the mobile data connectivity experience, allowing users to gain access to mobile data traffic allowance shared by network operators on its marketplace. It has aggregated mobile data traffic allowances from 391 MNOs in 163 countries and regions in its cloud SIM architecture. The company derives maximum revenue from Japan.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.